{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-013565","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.700193+00:00","generated_at":"2026-05-15T22:20:30.982854+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine FY2025 net loss $201.1M; WD/AATD IND filings on track, CGD BLA planned","bullets":["Net loss $201.1M for FY2025, cash $191.4M providing runway into 2027.","On track to file IND/CTA for Wilson Disease (1H 2026) and AATD (mid-2026); initial clinical data expected 2027.","Engaging FDA for PM359 in CGD; plans BLA based on Phase 1/2 data published in NEJM, targeting accelerated approval.","Workforce reduction and deprioritization of CGD program to focus on in vivo liver franchise.","CF program preclinical proof-of-concept data expected 2026; BMS CAR-T collaboration continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-013565","json":"https://secwatch.observer/filing/0001628280-26-013565.json","markdown":"https://secwatch.observer/filing/0001628280-26-013565.md","text":"https://secwatch.observer/filing/0001628280-26-013565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/0001628280-26-013565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/prme-20260303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:20:30.982854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}